MEDI4736

Phase 3Small molecule

AstraZeneca

MEDI4736 is one of 126 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Gastric CancerActive, not recruiting

OvarianActive, not recruiting

Urothelial CancerActive, not recruiting

Non-Small Cell Lung CarcinomaActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

OvarianPreclinical

Active, not recruiting

Urothelial CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

MEDI4736

AstraZeneca

Phase 3

3 2

Adenocard

Astellas

Preclinical

2 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Muscle-Invasive Bladder Cancer

NCT02546661

Phase 3Active, not recruiting

Non-Small Cell Lung Carcinoma

NCT02453282

Phase 3Active, not recruiting

Urothelial Cancer

NCT02516241

Q2 2027

Phase 2Active, not recruiting

Gastric Cancer

NCT02678182

Q4 2028

PreclinicalActive, not recruiting

Triple-Negative Breast Cancer

NCT03616886

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02088112·56 enrolled

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02125461·713 enrolled

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Completed·SSwiss Cancer Institute·Phase 2·NCT02572843·68 enrolled

Show 2 more trials

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02000947·459 enrolled

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Completed·CCanadian Cancer Trials Group·Phase 3·NCT02273375·1,415 enrolled

Squamous Cell Carcinoma3 trials

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02319044·267 enrolled

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02499328·340 enrolled

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02207530·112 enrolled

Advanced Solid Tumours3 trials

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02617277·56 enrolled

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02586987·58 enrolled

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01938612·269 enrolled

Breast Cancer3 trials

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Completed·YYale University·Phase 1/2·NCT02489448·68 enrolled

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT02685059·174 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Advanced Solid Tumors2 trials

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Completed·KKyowa Kirin, Inc.·Phase 1·NCT02301130·64 enrolled

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02261220·380 enrolled

25 more indications

Head and Neck Cancer2 trials

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02262741·71 enrolled

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02369874·736 enrolled

Small Cell Lung Cancer2 trials

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087423·446 enrolled

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02352948·597 enrolled

Metastatic Head and Neck Cancer1 trial

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02551159·823 enrolled

Monotherapy1 trial

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02454933·29 enrolled

Malignant Pleural Mesothelioma1 trial

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Completed·—·Phase 2·NCT02592551·24 enrolled

Relapsed/Refractory1 trial

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02549651·32 enrolled

Selected Advanced Solid Tumors1 trial

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Completed· Incyte logo

Incyte·Phase 1/2·NCT02318277·176 enrolled

Gastrointestinal1 trial

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02572687·85 enrolled

Metastatic Melanoma1 trial

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed·—·Phase 1·NCT02639026·53 enrolled

Papilloma1 trial

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Terminated·AAdvaxis, Inc.·Phase 1/2·NCT02291055·75 enrolled

Adenocarcinoma1 trial

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02340975·114 enrolled

Renal Cell Carcinoma1 trial

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Completed·QQueen Mary University of London·Phase 2·NCT02819596·69 enrolled

Pancreatic Cancer1 trial

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Withdrawn·NNYU Langone Health·Phase 1·NCT02868632

Colorectal Cancer1 trial

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02227667·16 enrolled

Metastasis1 trial

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Terminated·WWashington University School of Medicine·Phase 2·NCT02669914·4 enrolled

Mesothelioma1 trial

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02141347·65 enrolled

Phase 11 trial

A Phase 1/2 Study to Evaluate MEDI4736

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT01693562·1,022 enrolled

Advanced Solid Malignancies1 trial

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03084471·867 enrolled

Gastric Cancer1 trial

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02678182·494 enrolled

Lymphoma1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02401048·61 enrolled

Triple-Negative Breast Cancer1 trial

A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Active, not recruiting·JJules Bordet Institute·Preclinical·NCT03616886·129 enrolled

Muscle-Invasive Bladder Cancer1 trial

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT02546661·117 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02453282·1,118 enrolled

Ovarian1 trial

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT02734004·264 enrolled

Urothelial Cancer1 trial

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02516241·1,126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for MEDI4736. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEDI4736 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEDI4736. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

MEDI4736

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

Squamous Cell Carcinoma3 trials

Advanced Solid Tumours3 trials

Breast Cancer3 trials

Advanced Solid Tumors2 trials

Head and Neck Cancer2 trials

Small Cell Lung Cancer2 trials

Metastatic Head and Neck Cancer1 trial

Monotherapy1 trial

Malignant Pleural Mesothelioma1 trial

Relapsed/Refractory1 trial

Selected Advanced Solid Tumors1 trial

Gastrointestinal1 trial

Metastatic Melanoma1 trial

Papilloma1 trial

Adenocarcinoma1 trial

Renal Cell Carcinoma1 trial

Pancreatic Cancer1 trial

Colorectal Cancer1 trial

Metastasis1 trial

Mesothelioma1 trial

Phase 11 trial

Advanced Solid Malignancies1 trial

Gastric Cancer1 trial

Lymphoma1 trial

Triple-Negative Breast Cancer1 trial

Muscle-Invasive Bladder Cancer1 trial

Non-Small Cell Lung Carcinoma1 trial

Ovarian1 trial

Urothelial Cancer1 trial

References

Drug Info

Quick Facts

Related News